Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Nike Inc (NKE) Price & Performance

BioNTech SE - ADRTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Nike Inc — how do they compare? BioNTech SE - ADR trades at $93.27 (market cap $23.31B), while Nike Inc trades at $40.69 (market cap $61.30B). The key difference: Nike Inc is far larger — about 2.6× BioNTech SE - ADR's market cap, and Nike Inc pays a 3.97% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

BNTXNKE
Market Cap
$23.31B$61.30B
Sector
HealthConsumer Cyclical
52-Week High
$119.34$79.17
52-Week Low
$83.89$40.75
Enterprise Value
$6.60B$63.30B
Volume
8,887,180
Dividend Yield
3.97%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.

The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.

Nike Inc

Nike (NKE) trades at $42.11, up 0.98% on the day, showing resilience amid a challenging period. The stock faces bearish technical signals but maintains strong profitability metrics including 42.91% gross margin and 22.14% ROE. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.72 significantly exceeding the $0.11 forecast. However, revenue declined to $46.31B in 2025 from $51.4B in 2024, reflecting ongoing business headwinds.

Nike's investment case balances strong brand value and consistent earnings beats against revenue pressures and competitive challenges. The consensus price target of $50.45 suggests 20% upside potential, though technical indicators remain bearish. Key risks include China market weakness and inventory management issues, while opportunities lie in digital transformation and product innovation driving future growth.

Returns comparison

Trailing returns across standard periods

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Nike Inc

NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.

Read more on NKE